A meta-analysis including 3,493 patients with rheumatoid arthritis who received TNF inhibitors (infliximab and adalimumab) and 1,512 patients who received placebo showed more malignancies (0.8%) in the TNF-inhibitor group compared with those who received placebo (0.2%), with a pooled odds ratio of 3.3 (95% CI, 1.2 to 9.1). The gene discussed is TNF; the disease is rheumatoid arthritis.